xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology.
First posted on NewsDirect
In a step forward for healthcare research, xCures is pleased to announce that it will support Aetion®’s collaboration with the US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). As part of this partnership, xCures will provide Aetion with data to support their research collaboration agreement with OCE which centers on using real-world data (RWD) to assess real-world oncology endpoints and measure and address health disparities.
As part of the collaboration with OCE, Aetion’s comprehensive fit-for-purpose data assessment identified xCures’ real-time, regulatory-grade data platform to be an appropriate fit for this research study, particularly its ability to integrate clinical data with patient pathology, radiology reports, and imaging assessments.
“Aetion is proud to embark on this partnership with xCures to help OCE conduct pivotal research to advance the use of real-world evidence, including in measuring and understanding vulnerable and underrepresented populations,” said Liz Garry, Head of Scientific Research, Aetion. “This work furthers our mission to power critical decisions in healthcare with data science-driven technology and brings us one step closer to achieving health equity.”
xCures’ CEO, Mika Newton, explains, “Our platform’s automated organization and structuring of aggregated, continuous data result in complete, source-verifiable, and fully longitudinal clinical data sets. This rich dataset can offer unprecedented insight into the real-world patient experience.”
The contribution of robust RWD from xCures will play an integral role in this endeavor, aiming to fill knowledge gaps and facilitate advancements in healthcare research. For more information about real-time, regulatory-grade clinical data, please visit www.xcures.com/solutions.
Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us on LinkedIn.
xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.
The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions.
The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.